Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in adult males, South China

Jun-Jie Liu, Yuan-Yuan Chen, Zeng-Nan Mo, Gui-Xiang Tian, Ai-Hua Tan, Yong Gao, Xiao-Bo Yang, Hai-Ying Zhang, Zhi-Xian Li, Jun-Jie Liu, Yuan-Yuan Chen, Zeng-Nan Mo, Gui-Xiang Tian, Ai-Hua Tan, Yong Gao, Xiao-Bo Yang, Hai-Ying Zhang, Zhi-Xian Li

Abstract

Aim: To determine serum osteocalcin levels in South Chinese males with non-alcoholic fatty liver disease (NAFLD) and to examine the relation between serum osteocalcin and NAFLD.

Methods: Data were collected from 1683 men attending the Fangchenggang Area Male Healthy and Examination Survey (FAMHES) from September 2009 to December 2009. Serum osteocalcin was measured with electrochemiluminescence immunoassay. An abdominal ultrasonographic examination for all individuals was performed by two experienced ultrasonographers. The associations of serum osteocalcin with NAFLD were evaluated.

Results: The levels of serum osteocalcin were lower in 364 NAFLD participants than in 1319 non-NAFLD participants (24.51 ± 1.38 ng/mL vs. 20.81 ± 1.33 ng/mL, p < 0.001). Serum osteocalin level was associated with the scale of NAFLD (r = -0.150, p < 0.01). Serum osteocalin level tended to decrease with the scale of NAFLD. Binary logistic regression analysis showed that decreased ORs for NAFLD were observed from the first to the fourth osteocalcin quartiles.

Conclusions: Our findings suggest that a lower serum osteocalcin level is associated with the presence of NAFLD.

Figures

Figure 1
Figure 1
Prevalence of non-alcoholic fatty liver disease (NAFLD) in different quartiles of osteocalcin. The prevalence of NAFLD from the lowest to highest osteocalcin quartile were 30.62%, 26.95%, 20.19%, 9.26%, respectively (p < 0.001).

References

    1. Adams L.A., Angulo P., Lindor K.D. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899–905.
    1. Hou X.H., Zhu Y.X., Lu H.J., Chen H.F., Li Q., Jiang S., Xiang K.S., Jia W.P. Non-alcoholic fatty liver disease’s prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese. J. Gastroenterol. Hepatol. 2011;26:722–730.
    1. Fan J.G., Saibara T., Chitturi S., Kim B.I., Sung J.J., Chutaputti A Asia-Pacific Working Party for NAFLD. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific. J. Gastroenterol. Hepatol. 2007;22:794–800.
    1. Amarapurkar D.N., Hashimoto E., Lesmana L.A., Sollano J.D., Chen P.J., Goh K.L. Asia-Pacific Working Party on NAFLD. How common is non–alcoholic fatty liver disease in the Asia–Pacific region and are there local differences. J. Gastroenterol. Hepatol. 2007;22:788–793.
    1. Fan J.G., Farrell G.C. Epidemiology of non–alcoholic fatty liver disease in China. J. Hepatol. 2009;50:204–210.
    1. McCullough A.J. Pathophysiology of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2006;40:S17–S29.
    1. Utzschneider K.M., Kahn S.E. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2006;91:4753–4761.
    1. Jornayvaz F.R., Samuel V.T., Shulman G.I. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annu. Rev. Nutr. 2010;30:273–290.
    1. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., Dacquin R., Mee P.J., McKee M.D., Jung D.Y., et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456–469.
    1. Ducy P. The role of osteocalcin in the endocrine cross–talk between bone remodelling and energy metabolism. Diabetologia. 2011;54:1291–1297.
    1. Pittas A.G., Harris S.S., Eliades M., Stark P., Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J. Clin. Endocrinol. Metab. 2009;94:827–832.
    1. Tan A.H., Gao Y., Yang X.B., Zhang H.Y., Qin X., Mo L.J., Peng T., Xia N., Mo Z.N. Low serum osteocalcin level is a potential marker for metabolic syndrome: Results from a Chinese male population survey. Metabolism. 2011;60:1186–1192.
    1. Fernández-Real J.M., Ortega F., Gómez-Ambrosi J., Salvador J., Frühbeck G., Ricart W. Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss. Osteoporos. Int. 2010;21:2101–2107.
    1. Dou J., Ma X., Fang Q., Hao Y., Yang R., Wang F., Zhu J., Bao Y., Jia W. Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in Chinese men. Clin. Exp. Pharmacol. Physiol. 2013;40:282–288.
    1. Yilmaz Y., Kurt R., Eren F., Imeryuz N. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration. Scand. J. Clin. Lab. Invest. 2011;71:631–636.
    1. Yilmaz Y. Review article: Non-alcoholic fatty liver disease and osteoporosis-clinical and molecular crosstalk. Aliment. Pharmacol. Ther. 2012;36:345–352.
    1. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., Mullen K.D., Cooper J.N., Sheridan M.J. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.
    1. Aller R., Castrillon J.L., de Luis D.A., Conde R., Izaola O., Sagrado M.G., Velasco M.C., Alvarez T., Pacheco D. Relation of osteocalcin with insulin resistance and histopathological changes of non alcoholic fatty liver disease. Ann. Hepatol. 2011;10:50–55.
    1. Cusi K., Chang Z., Harrison S., Lomonaco R., Bril F., Orsak B., Ortiz-Lopez C., Hecht J., Feldstein A.E., Webb A., et al. Limited Value of Plasma Cytokeratin-18 as a Biomarker for NASH and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) J. Hepatol. 2013 doi: 10.1016/j.jhep.2013.07.042..
    1. Musso G., Bo S., Cassader M., de Michieli F., Gambino R. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. Am. J. Clin. Nutr. 2013;98:895–906.
    1. Adams L.A., Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad. Med. J. 2006;82:315–322.
    1. Yeap B.B., Chubb S.A.P., Flicker L., McCaul K.A., Ebeling P.R., Beilby J.P., Norman P.E. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur. J. Endocrinol. 2010;163:265–272.
    1. Saleem U., Mosley T.H., Jr., Kullo I.J. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2010;30:1474–1478.
    1. Zhou M., Ma X., Li H., Pan X., Tang J., Gao Y., Hou X., Lu H., Bao Y., Jia W. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur. J. Endocrinol. 2009;161:723–729.
    1. Adams L.A., Talwalkar J.A. Diagnostic evaluation of nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 2006;40:S34–S38.
    1. Mottin C.C., Moretto M., Pan A.V., Swarowsky A.M., Toneto M.G., Glock L., Repetto G. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes. Surg. 2004;14:635–637.
    1. Joy D., Thava V.R., Scott B.B. Diagnosis of fatty liver disease: Is biopsy necessary. Eur. J. Gastroenterol. Hepatol. 2003;15:539–543.
    1. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705–1725.
    1. Fan J.G. Chinese Liver Disease Association. Guidelines for management of nonalcoholic fatty liver disease: An updated and revised edition. Chin. J. Hepatol. 2010;18:163–166.
    1. Meziri M., Pereira W.C., Abdelwahab A., Degott C., Laugier P. In vitro chronic hepatic disease characterization with a multiparametric ultrasonic approach. Ultrasonics. 2005;43:305–313.
    1. Pulzi F.B., Cisternas R., Melo M.R., Ribeiro C.M., Malheiros C.A., Salles J.E. New clinical score to diagnose nonalcoholic steatohepatitis in obese patients. Diabetol. Metab. Syndr. 2011 doi: 10.1186/1758-5996-3-3..

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera